Talking About Tumors with Ryann and Ryan - A medical oncology podcast
Talking About Tumors
50 episodes
6 months ago
1. Nomenclature, unique considerations 2. Secretory Syndromes 3. Somatostatin directed therapy 4. Peptide Receptor Radionucleotide Therapy Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice. DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and ...
All content for Talking About Tumors with Ryann and Ryan - A medical oncology podcast is the property of Talking About Tumors and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
1. Nomenclature, unique considerations 2. Secretory Syndromes 3. Somatostatin directed therapy 4. Peptide Receptor Radionucleotide Therapy Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice. DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and ...
Talking About Tumors with Ryann and Ryan - A medical oncology podcast
24 minutes
1 year ago
04_08 Metastatic Renal Cell Carcinoma
1. Historical Approach (cytoreduction, IFN-a, sunitinib2. Prognostic risk scores3. Evidence for modern doublet regimens4. Later line therapyCitationsAs always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice. DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and R...
Talking About Tumors with Ryann and Ryan - A medical oncology podcast
1. Nomenclature, unique considerations 2. Secretory Syndromes 3. Somatostatin directed therapy 4. Peptide Receptor Radionucleotide Therapy Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice. DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and ...
